Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Renal Ageing-sarcopenia Network

9 dicembre 2020 aggiornato da: Paolo Manunta, IRCCS San Raffaele

Renal Ageing-sarcopenia Network: a Combined Genetic, Immunological and Psychological Approach to Dissect Frailty

Frailty is a syndrome in which the accumulation of small, individually insignificant deficits leads to heightened vulnerability to adverse events and predisposes to potential catastrophic decompensation.

Objective of this study is to clarify the underlying genetic and immunological mechanisms responsible of frailty condition focused on: i. nephrosclerosis ageing kidney phenotype related to salt effects on immunosystem, ii. immunological aspect of sarcopenia, iii. psychological disorder related to immunosystem activation, iv. detection of new biomarkers of frailty.

Panoramica dello studio

Stato

Sconosciuto

Descrizione dettagliata

The cross-sectional, observational cohort study include 1500 subjects (age >65 years) subdivided in 750 cases and 750 controls according to frailty.

Subjects who met the following criteria are included: 1) older than 65; 2) able to walk 500 m without assistance; 3) a Mini-Mental State Examination (MMSE) score <18; and 4) no severe health problems (eg, uncontrolled hypertension, recent upper or lower extremity fractures, myocardial infarction within the past 1 year).

According to definition for the 'phenotype' of frailty (cases) is as follows: presence of three or more of the following features:

  1. Decreased grip strength
  2. Self-reported exhaustion
  3. Unintentional weight loss of more than 4.5 kg over the past year
  4. Slow walking speed
  5. Low physical activity

The investigators select as control subjects with presence of less than 1 criteria . All the control subjects are evaluated by the same protocol than the cases. Subjects will be collected in collaboration with senior housing (RSA) of Milano city, country clubs, social club for elderly, and elderly university. The study will be approved by the Ethics Committee of ASL of Milano city and at individual centers by local ethical committees. All the study participants signed informed consent. At the baseline evaluation, a large amount of data is collected. First, the participants completed a battery of self-reported questionnaires concerning the demographic characteristics, psychosocial adjustment, quality of life, and health condition, in the presence of a trained psychologist in order to clarify any doubts. Second, an expert in physical education and adapted physical activity for older adults administered physical tests. Finally, people with expertise in the eld of ergonomics take anthropometric measurements. Data collection is always carried out in the same order and individually for each participant.

In all the subjects following clinical and laboratoristic data are collected:

1. Clinical evaluation:

  1. Collection of anamnestic data.
  2. Blood pressure measurement. Blood pressure is measured by a trained nurse using an authomatic device (OMRON) and an appropriately sized cuff. Readings are obtained after 5 min of seated rest. The mean of 3 blood pressure measurements obtained at 1-min intervals during the medical evaluation is used to define SBP and DBP.
  3. Evaluation of kidney function :

    a. CKD is defined as a glomerular filtration rate (GFR) lower than 60 mL/min/1.73 m2 or markers of kidney damage, such as albuminuria,for greater than 3 months. A creatinine-based formula is used to estimate GFR, applying Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equations.

    b. Urine analysis and albumin /creatinine and sodium /creatinine ratio urinary excretion.

2. Physical frailty measure. To identify physically frail older adults, an adapted version of the frailty phenotype of Fried et al is used. Subjects with three or more criteria are classified as frail, those with one or two as prefrail, and those meeting none as robust.

  1. Body composition: Height and weight are detected. Bioimpedance analysis (BIA) is a system of evaluation of body composition, able to calculate adjunctive information: total body water (TBW), extra and intracellular water (ECW and ICW), body cell mass (BCM), muscle mass (MM), fat mass (FM), fat free mass (FFM), basal metabolic rate.
  2. SPPB: The short physical performance battery (SPPB) is a group of measures that combines the results of the gait speed, chair stand and balance tests. It has been used as a predictive tool for possible disability and can aid in the monitoring of function in older people. The scores range from 0 (worst performance) to 12 (best performance).
  3. PASE: Physical Activity Scale for the Elderly (PASE) is a brief (5 minutes) and easily scored survey designed specifically to assess physical activity in epidemiological studies of persons age 65 years and older. The PASE score combines information on leisure, household and occupational activity. The PASE assesses the types of activities typically chosen by older adults (walking, recreational activities, exercise, housework, yard work, and caring for others. It uses frequency, duration, and intensity level of activity over the previous week to assign a score, ranging from 0 to 793, with higher scores indicating greater physical activity.

Sarcopenia will be defined as fat-free mass index (FFMI) below the 25th percentile combined with one of the following functional parameter: either an SPPB score ≤8 or a comfortable gait speed <1.0 m/s.

3. Psychological test will be used to assess self conditions

  1. Mini Mental State Examination (MMSE): The Mini-Mental Stat Examination (MMSE) is a 10-minute measure of cognitive impairment in undeveloped, uneducated, diseased, or very old populations.
  2. Geriatric Depression Scale-short form (GDS-15): The Geriatric Depression Scale (GDS) is a 15- item self-report validated measure for rating depression in elderly adults. Additionally, the GDS is sensitive to depression among elderly adults suffering from mild to moderate dementia and elderly adults with physical illnesses by excluding questions pertaining to somatic complaints and cognitive dimension of depression. In this scale, a score of 6 or higher may be indicative of depression and must be evaluated jointly with patient's clinical data.
  3. SF-36 Medical Outcomes Study (MOS) 36-item Short Form Health Survey: This instrument should capture both mental and physical aspects of health. The 36 6-likert item assess health across eight domains, namely bodily pain, general health perceptions, mental health, physical functioning, role limitations due to emotional health problems, role limitations due to physical health problems, social functioning, and vitality. All items use categorical response options (range: 2-6 options). Two component summary scores for physical and mental health (MPS and MCS, respectively) can also be calculated.

4. Laboratory Methods

  1. Genotyping. OpenArray technology (ThermoFisher) for genetic characterization of Single Nucleotide Polymorphisms (SNPs), based on TaqMan chemistry. DNA will be used for genotyping of genetic variants in loci for Klotho (KL) gene, Adducins (ADD1, ADD2 and ADD3) and EO synthesis (LSS, HSD3B1), metabolism (CYP11A1, ABCB1), and activity (SLC8A1, SIK1) genes, and for immunological pathway (TLR4, HMGB1, IL6, IL1).
  2. Biochemical measurements.

    1. Endogenous Ouabain measurement
    2. Plasma Klotho measurement.
  3. Immunological determinations. Simultaneous assessment of serum concentrations of epidermal growth factor (EGF), fibroblast growth factor 2 (FGF2), FMS-like tyrosine kinase 3 ligand (Flt-3L), granulocyte colony-stimulating factor (G-CSF), granulocyte-monocyte colonystimulating factor (GM-CSF), interferon-α2 (IFN-α2), INF-γ, IL-10, IL-15, IL-17, IL-1β, IL-2, IL-6, IL-8, INF-γ inducible protein 10 (IP-10), monocyte chemoattractant protein-1 (MCP-1), macrophage inflammatory protein-1β (MIP-1 β), platelet-derived growth factor-AA (PDGF-AA), soluble CD40 ligand (sCD40L), transforming growth factor alpha (TGF-α), TNF-α and vascular endothelial growth factor (VEGF).

Tipo di studio

Osservativo

Iscrizione (Anticipato)

1500

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

Luoghi di studio

      • Milan, Italia, 20132
        • Reclutamento
        • IRCCS Ospedale San Raffaele

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

65 anni e precedenti (Adulto più anziano)

Accetta volontari sani

Sessi ammissibili allo studio

Tutto

Metodo di campionamento

Campione non probabilistico

Popolazione di studio

Community sample of the elderly population

Descrizione

Inclusion Criteria:

  • Age ≥ 65 years
  • Male and female patients
  • Patients able to walk > 500 m without assistance
  • MMSE < 18
  • No severe health problems (Uncontrolled hypertension, recent upper or lower extremity fractures, myocardial infarction within the past 1 year).

Exclusion Criteria:

  • Severe cardiological or pulmonary disease (NYHA IV, Gold IV)
  • Intracranial interventions
  • Dying patients (palliative situation)
  • Not enough language skills
  • Non-consenting patients
  • Participation in another prospective intervention study for study inclusion or throughout the study period.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

Coorti e interventi

Gruppo / Coorte
Frailty Group

The 'phenotype' of frailty (cases) is defined as follows: presence of three or more of the following features:

  1. Decreased grip strength
  2. Self-reported exhaustion
  3. Unintentional weight loss of more than 4.5 kg over the past year
  4. Slow walking speed
  5. Low physical activity
Non-Frailty Group

The 'phenotype' of non-frailty (control) is defined as follows: presence of less than three of the following features:

  1. Decreased grip strength
  2. Self-reported exhaustion
  3. Unintentional weight loss of more than 4.5 kg over the past year
  4. Slow walking speed
  5. Low physical activity

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Correlation between Frailty and Klotho polymorphism, assessed by Fried Classification: non-frail (score 0), pre-frail (score 1-2) and frail (score 3-5)
Lasso di tempo: 3 years
Verifying the role of the polymorphism of the Klotho gene in the development of the "fragility" phenotype in elderly subjects.
3 years

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Correlation between Frailty and Klotho (KL), Adducine (ADD1, ADD2 and ADD3), Lanosterol and other polymorphisms, assessed by Fried Classification: non-frail (score 0), pre-frail (score 1-2) and frail (score 3-5)
Lasso di tempo: 3 years
Finding genetic profiles predisposing to the development of frailty through genotyping for Klotho (KL), Adducine (ADD1, ADD2 and ADD3), Lanosterol and further polymorphisms in genes related to renal function and the immune system.
3 years
Correlation between Frailty and plasmatic values of endogenous ouabain, Klotho and plasma cytokines, assessed by Fried Classification: non-frail (score 0), pre-frail (score 1-2) and frail (score 3-5)
Lasso di tempo: 3 years
Studying the role of biomarkers in the development of frailty: endogenous ouabain, Klotho and plasma cytokines.
3 years
Creation of a multidisciplinary frailty score, based on the outcomes of the study
Lasso di tempo: 3 years
Building a multidisciplinary frailty score based on biochemical, genetic and psychological results of the study.
3 years

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Collaboratori

Investigatori

  • Investigatore principale: Paolo Manunta, PhDMD, IRCCS San Raffaele

Pubblicazioni e link utili

La persona responsabile dell'inserimento delle informazioni sullo studio fornisce volontariamente queste pubblicazioni. Questi possono riguardare qualsiasi cosa relativa allo studio.

Pubblicazioni generali

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

25 marzo 2017

Completamento primario (Anticipato)

31 marzo 2021

Completamento dello studio (Anticipato)

31 marzo 2021

Date di iscrizione allo studio

Primo inviato

10 novembre 2020

Primo inviato che soddisfa i criteri di controllo qualità

13 novembre 2020

Primo Inserito (Effettivo)

16 novembre 2020

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

11 dicembre 2020

Ultimo aggiornamento inviato che soddisfa i criteri QC

9 dicembre 2020

Ultimo verificato

1 dicembre 2020

Maggiori informazioni

Termini relativi a questo studio

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

Periodo di condivisione IPD

Clinical data and sample alredy collectd are available,

Tipo di informazioni di supporto alla condivisione IPD

  • STUDIO_PROTOCOLLO
  • ICF
  • RSI

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

3
Sottoscrivi